[ABO血型不合对异基因造血干细胞移植结局的影响]

[Effect of ABO-Incompatibility on Outcome of Allogeneic Hematopoietic Stem Cell Transplantation].

作者信息

Yang Bing-Bing, Gan Yi-Feng, Chen Peng, Chen Yi, Yu Kang

机构信息

Department of Hematology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325015, Zhejiang Province, China.

Department of Hematology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325015, Zhejiang Province, China. E-mail:

出版信息

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2017 Apr;25(2):535-540. doi: 10.7534/j.issn.1009-2137.2017.02.041.

DOI:10.7534/j.issn.1009-2137.2017.02.041

PMID:28446307

Abstract

OBJECTIVE

To investigate the effect of ABO-incompatibility on the efficacy and complications of allogeneic hematopoietic stem cell transplantation(HSCT).

METHODS

The clinical data of 54 recipients who received ABO-incompatible allo-HSCT were retrospectively analyzed and were compared with 54 ABO-identical recipients as controls. Hematopoietic reconstruction and the blood type conversion time were dynamically observed and compared between 2 groups.

RESULTS

The time of erythrocyte reconstitution was prolonged to 24 d in ABO-incompatible group, compared with that of 19 d in ABO-compatible group (P<0.01). The difference of neutrophil and platelet reconstruction was not statistically significant (P>0.05). Major mismatch group and bidirectional mismatch group required more erythrocyte transfusions than that of ABO-compatible group. The surface antigen of erythrocyte change in major mismatch group was earlier than that of minor mismatch group (P<0.05). The incidence of cytomegalovirus (CMV) infection, acute graft versus host disease (aGVHD) and survival were not significantly different between 2 groups.

CONCLUSION

ABO-incompatibility can not influence the effect of allo-HSCT, but ABO-incompatibility delayed erythrocyte recovery, and required more RBC and platelet transfusions.

摘要

目的

探讨ABO血型不合对异基因造血干细胞移植（HSCT）疗效及并发症的影响。

方法

回顾性分析54例接受ABO血型不合异基因HSCT受者的临床资料，并与54例ABO血型相合受者作为对照。动态观察并比较两组的造血重建及血型转换时间。

结果

ABO血型不合组红细胞重建时间延长至24天，而ABO血型相合组为19天（P<0.01）。中性粒细胞和血小板重建差异无统计学意义（P>0.05）。主要错配组和双向错配组比ABO血型相合组需要更多的红细胞输血。主要错配组红细胞表面抗原变化早于次要错配组（P<0.05）。两组间巨细胞病毒（CMV）感染、急性移植物抗宿主病（aGVHD）发生率及生存率差异无统计学意义。